Galena To Pay $20M To End Investor Suits Over Deceptive PR
Galena Biopharma Inc. and its brass have agreed to pay $20 million to settle a securities class action and a derivative suit accusing them of inflating the company's share price with...To view the full article, register now.
Already a subscriber? Click here to view full article